NPPA Extends Time Limit For Submission Of Production, Price Data Till February 15

New Delhi : The National Pharmaceutical Pricing Authority (NPPA) has extended the last date of filing statutory forms related to quarterly production and sales data for scheduled drugs and medical devices for the two quarters ended September and December, 2022, for a period of up to February 15, 2023.

It has earlier issued a direction extending the time limit for the filing of these data for the quarter of September, 2022, for three months till December 31, 2022 after the Authority received several representations from the industry requesting for extension of the last date for filing.

The industry needs to periodically file the statutory Form III (for submission of quarterly return in respect of production/import and sale data for drugs under the National List of Essential Medicines), Form V (which is an intimation about the Maximum Retail Price change of scheduled and non-scheduled drugs), and Form VI (which is to intimate the Authority regarding the MRP change of medical devices) with the NPPA as per the Drug (Prices Control) Order, 2013.

While the data under Form III has to be submitted within fifteen days from the end of the quarter as per the rules, for the quarter ending September and December, 2022, it can be filed up to February 15, 2023.

Similarly, for any MRP revision done between August 1 to December 15, 2022, the Form V can be filed up to January 31, 2023, as against the prescribed time limit of fifteen days from the date of price revision, can be filed in Form V up to February 15, 2023.

Under the Form VI, which was inserted by the Department of Pharmaceutical through an order on July 20, 2021, for the intimation about MRP change of medical devices, has to be filed within a period of fifteen days of price revision, according to the price regulation. The NPPA, through the office memorandum, stated that for any MRP revision done between August 1 and January 31, 2023, the Form VI can be filed up to February 15, 2023.

The NPPA has issued a similar Office Memorandum in September 21, 2022, extending the time limit for submitting the data under these three forms for the quarter ending September, upto December 31, 2022.

The Authority in the past also issued orders extending the time limit for submission of the Forms related to the production and sales and price data for drugs and medical devices in response to the requests from the industry.

The forms have to be submitted through IPDMS 2.0, implemented by the NPPA for online information collection from pharmaceutical manufacturers to monitor and regulate the pharma and medical devices prices, to ensure availability and affordability of drugs and medical devices in the country.

  • Related Posts

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    Chandauli – In yet another shocking case of alleged fraud in Uttar Pradesh’s health department, an FIR has been registered against a pharmacist for securing and continuing employment for nearly…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    Laughing all the Way to Health with Sir Ganga Ram Hospital

    Laughing all the Way to Health with Sir Ganga Ram Hospital

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections